内血管瘤封闭术后中期治疗失败的模式:迁移与瘤囊扩张
本研究前瞻性收集2013年至2018年295例接受Nellix内血管瘤封闭(EVAS)治疗的腹主动脉瘤患者数据,随访中位2.42年。总体治疗失败率33.2%,部分亚组超过50%,失败多见于术后2年以上,二次破裂率5.36%。Nellix系统已被自愿召回,CE标志暂停。
要点
- EVAS术后治疗失败率高,总体达33.2%,部分亚组超过50%。
- 治疗失败多见于术后2年及以后,需长期严密随访。
- 二次破裂率5.36%,9例装置需取出,Nellix系统已被召回。
核心结论
- Nellix EVAS未达到预期效果,早期乐观结果已被侵蚀,治疗失败率高且多发生于术后2年及以后。
研究设计与样本
- 前瞻性收集2013年3月至2018年7月共295例EVAS病例,包括肾下型185例、近肾/肾上型73例、破裂型18例、髂动脉型13例,以及15例Nellix-in-Nellix再干预。
主要发现
- 总体治疗失败率为33.2%(98/295),部分亚组超过50%。
- 24.1%(71例)接受了再干预,未再干预的主要原因为生理性。
- 二次破裂15例(5.36%),9例EVAS装置需择期或因破裂取出。
- 中位随访2.42年(四分位距1.07-3.57年),失败并发症最常见于随访2年后。
关键数值与推荐
- 治疗失败定义为迁移、瘤囊扩张>5 mm、Ia型或Ib型内漏、二次主动脉破裂的复合终点。
临床怎么用
- EVAS术后应长期严密随访,特别关注2年后的迁移和瘤囊扩张。
- 鉴于高失败率,Nellix系统已被召回,CE标志暂停,临床应避免使用并加强已植入患者的监测。
局限性
- 单中心前瞻性队列,中位随访2.42年,部分亚组样本量较小。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Endovascular aneurysm sealing (EVAS) is a disruptive technology to treat abdominal aortic aneurysm (AAA). The use of sac filling rather than endograft fixation was designed to treat aortic aneurysms in a wide range of morphologic appearances and to reduce endoleaks. There are few data reporting outcomes beyond postoperative follow-up. This study reports outcomes up to 5 years for Nellix (Endologix, Irvine, Calif) EVAS. METHODS: Data were prospectively collected for EVAS patients from the time of adoption of EVAS in 2013. All patients treated with the Nellix device are included in this study, and as such, it reports on infrarenal, ruptured, and iliac aneurysms as well as the Nellix-in-Nellix application. Juxtarenal and suprarenal aneurysms were treated using the EVAS system with parallel grafts into the visceral vessels and are included. Therapeutic failure, a composite outcome of migration, sac expansion >5 mm, type Ia and type Ib endoleak, and secondary aortic rupture, was the primary outcome along with all-cause mortality, aneurysm-related mortality, and reintervention rates. RESULTS: There were 295 EVAS cases undertaken between March 2013 and July 2018. Indications for treatment were infrarenal (n = 185), juxtarenal and suprarenal (n = 73), ruptured (n = 18), and iliac (n = 13) aneurysms. There were 15 reinterventions using the Nellix-in-Nellix application. In some cases, EVAS was used to salvage failing endovascular or open aneurysm repairs. Median follow-up was 2.42 years (interquartile range, 1.07-3.57 years). Therapeutic failure was observed in 98 of the 295 cases (33.2%) overall and exceeded 50% in some subgroups. In 71 cases (24.1%), reintervention was performed, with reasons for no reintervention being mainly physiologic. Complications leading to therapeutic failure were most commonly seen beyond 2 years of follow-up. There were 15 secondary ruptures (5.36%), and 9 EVAS devices required explantation either electively or for aortic rupture. CONCLUSIONS: EVAS with the Nellix device has not met expectations, and early encouraging results have been eroded. The incidence of therapeutic failure has been high, occurring 2 years and beyond after implantation. The Nellix system has been voluntarily recalled by Endologix, and the CE mark has subsequently been suspended. The adoption of EVAS as a disruptive technology highlights the need for cautious adoption of novel technologies and the strict governance around such arrangements.
引用
- Stenson KM, de Bruin JL, Loftus IM, et al. Migration and sac expansion as modes of midterm therapeutic failure after endovascular aneurysm sealing. J Vasc Surg. 2019. PMID: 31405762. doi:10.1016/j.jvs.2019.04.482
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。